Clin Cancer Res:氟维司群+依维莫司+阿纳曲唑联合作一线治疗HR阳性晚期乳腺癌的效果

2021-12-02 Nebula MedSci原创

转移性激素受体阳性 (HR阳性)、HER2-阴性乳腺癌是癌症相关死亡的一个重要原因

转移性激素受体阳性 (HR阳性)、HER2-阴性乳腺癌是癌症相关死亡的一个重要原因。一直以来,内分泌治疗加或不加其他靶向治疗都是这类乳腺癌的主要治疗方法。

本试验旨在评估氟维司群联合依维莫司 vs 氟维司群联合依维莫司和阿纳曲唑作为一线方案治疗HR-阳性、HER2-阴性的晚期乳腺癌的效果

这是一项随机化的安慰剂为对照的临床试验,招募了绝经后的既往未接受过系统治疗的HR-阳性、HER2-阴性的晚期乳腺癌患者。受试患者被随机分至三组,接受氟维司群+依维莫司、氟维司群+依维莫司+阿纳曲唑或氟维司群单药治疗。主要终点是无进展生存期(PFS)。此外,在治疗前和第二个疗程开始前用两种不同的方法检测患者的循环肿瘤细胞(CTC)和循环肿瘤细胞DNA(ctDNA)。

各组的无进展生存期

2014年5月至2015年2月,部分由于临床实践的变化,这项研究在只招募了37位患者后就停止了。与单用氟维司群相比,没有证据表明含有依维莫司的联合治疗可改善这类晚期乳腺癌患者的无进展生存期或总生存期。各组的无进展生存期相近,总体中位PFS为11.2个月;总体中位总生存期为42个月。

各组的总生存期

在36位可评估患者中,氟维司群组未发生3级及以上的毒性反应。氟维司群联合依维莫司组有一位患者发生了4级的毒性反应(低磷血症),此外,还有10位接受氟维司群联合依维莫司(有或无阿纳曲唑)治疗的患者发生了3级的毒性反应。连续建模时,研究人员观察到基线CTC和ctDNA与较差的生存预后之间存在相关性。

总而言之,虽然该研究的规模有限,但研究结果不支持在激素阳性的晚期乳腺癌的一线治疗中常规使用依维莫司联合内分泌治疗

原始出处:

Halle C.F. Moore, William E. Barlow, et al. A randomized trial of fulvestrant, everolimus and anastrozole for the front-line treatment of patients with advanced hormone receptor-positive breast cancer, SWOG S1222. Clin Cancer Res November 29 2021 DOI:10.1158/1078-0432.CCR-21-3131

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1954156, encodeId=2557195415666, content=<a href='/topic/show?id=ab4291261f' target=_blank style='color:#2F92EE;'>#HR阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9126, encryptionId=ab4291261f, topicName=HR阳性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Thu Apr 14 14:37:40 CST 2022, time=2022-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077051, encodeId=35e210e7051e9, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210526/d8036608a81e44d183c185e06517e1cf/fd173bc0aba64070b54b049cedcc6bce.jpg, createdBy=41cf5507885, createdName=豪杰克, createdTime=Sun Dec 05 11:23:09 CST 2021, time=2021-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076506, encodeId=e74b10e65065c, content=好用, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d9a5236987, createdName=10188348, createdTime=Fri Dec 03 10:46:36 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076409, encodeId=31bb10e64092e, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Fri Dec 03 06:10:20 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076387, encodeId=dd1410e638736, content=学到了,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95c05717605, createdName=ms3000000092726127, createdTime=Thu Dec 02 23:06:18 CST 2021, time=2021-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076380, encodeId=adde10e6380ab, content=不错,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Thu Dec 02 22:55:49 CST 2021, time=2021-12-02, status=1, ipAttribution=)]
    2022-04-14 仁医06
  2. [GetPortalCommentsPageByObjectIdResponse(id=1954156, encodeId=2557195415666, content=<a href='/topic/show?id=ab4291261f' target=_blank style='color:#2F92EE;'>#HR阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9126, encryptionId=ab4291261f, topicName=HR阳性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Thu Apr 14 14:37:40 CST 2022, time=2022-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077051, encodeId=35e210e7051e9, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210526/d8036608a81e44d183c185e06517e1cf/fd173bc0aba64070b54b049cedcc6bce.jpg, createdBy=41cf5507885, createdName=豪杰克, createdTime=Sun Dec 05 11:23:09 CST 2021, time=2021-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076506, encodeId=e74b10e65065c, content=好用, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d9a5236987, createdName=10188348, createdTime=Fri Dec 03 10:46:36 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076409, encodeId=31bb10e64092e, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Fri Dec 03 06:10:20 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076387, encodeId=dd1410e638736, content=学到了,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95c05717605, createdName=ms3000000092726127, createdTime=Thu Dec 02 23:06:18 CST 2021, time=2021-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076380, encodeId=adde10e6380ab, content=不错,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Thu Dec 02 22:55:49 CST 2021, time=2021-12-02, status=1, ipAttribution=)]
    2021-12-05 豪杰克

    不错

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1954156, encodeId=2557195415666, content=<a href='/topic/show?id=ab4291261f' target=_blank style='color:#2F92EE;'>#HR阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9126, encryptionId=ab4291261f, topicName=HR阳性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Thu Apr 14 14:37:40 CST 2022, time=2022-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077051, encodeId=35e210e7051e9, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210526/d8036608a81e44d183c185e06517e1cf/fd173bc0aba64070b54b049cedcc6bce.jpg, createdBy=41cf5507885, createdName=豪杰克, createdTime=Sun Dec 05 11:23:09 CST 2021, time=2021-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076506, encodeId=e74b10e65065c, content=好用, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d9a5236987, createdName=10188348, createdTime=Fri Dec 03 10:46:36 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076409, encodeId=31bb10e64092e, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Fri Dec 03 06:10:20 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076387, encodeId=dd1410e638736, content=学到了,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95c05717605, createdName=ms3000000092726127, createdTime=Thu Dec 02 23:06:18 CST 2021, time=2021-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076380, encodeId=adde10e6380ab, content=不错,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Thu Dec 02 22:55:49 CST 2021, time=2021-12-02, status=1, ipAttribution=)]
    2021-12-03 10188348

    好用

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1954156, encodeId=2557195415666, content=<a href='/topic/show?id=ab4291261f' target=_blank style='color:#2F92EE;'>#HR阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9126, encryptionId=ab4291261f, topicName=HR阳性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Thu Apr 14 14:37:40 CST 2022, time=2022-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077051, encodeId=35e210e7051e9, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210526/d8036608a81e44d183c185e06517e1cf/fd173bc0aba64070b54b049cedcc6bce.jpg, createdBy=41cf5507885, createdName=豪杰克, createdTime=Sun Dec 05 11:23:09 CST 2021, time=2021-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076506, encodeId=e74b10e65065c, content=好用, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d9a5236987, createdName=10188348, createdTime=Fri Dec 03 10:46:36 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076409, encodeId=31bb10e64092e, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Fri Dec 03 06:10:20 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076387, encodeId=dd1410e638736, content=学到了,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95c05717605, createdName=ms3000000092726127, createdTime=Thu Dec 02 23:06:18 CST 2021, time=2021-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076380, encodeId=adde10e6380ab, content=不错,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Thu Dec 02 22:55:49 CST 2021, time=2021-12-02, status=1, ipAttribution=)]
    2021-12-03 学医无涯

    学习一下

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1954156, encodeId=2557195415666, content=<a href='/topic/show?id=ab4291261f' target=_blank style='color:#2F92EE;'>#HR阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9126, encryptionId=ab4291261f, topicName=HR阳性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Thu Apr 14 14:37:40 CST 2022, time=2022-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077051, encodeId=35e210e7051e9, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210526/d8036608a81e44d183c185e06517e1cf/fd173bc0aba64070b54b049cedcc6bce.jpg, createdBy=41cf5507885, createdName=豪杰克, createdTime=Sun Dec 05 11:23:09 CST 2021, time=2021-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076506, encodeId=e74b10e65065c, content=好用, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d9a5236987, createdName=10188348, createdTime=Fri Dec 03 10:46:36 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076409, encodeId=31bb10e64092e, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Fri Dec 03 06:10:20 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076387, encodeId=dd1410e638736, content=学到了,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95c05717605, createdName=ms3000000092726127, createdTime=Thu Dec 02 23:06:18 CST 2021, time=2021-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076380, encodeId=adde10e6380ab, content=不错,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Thu Dec 02 22:55:49 CST 2021, time=2021-12-02, status=1, ipAttribution=)]
    2021-12-02 ms3000000092726127

    学到了,谢谢

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1954156, encodeId=2557195415666, content=<a href='/topic/show?id=ab4291261f' target=_blank style='color:#2F92EE;'>#HR阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9126, encryptionId=ab4291261f, topicName=HR阳性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Thu Apr 14 14:37:40 CST 2022, time=2022-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077051, encodeId=35e210e7051e9, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210526/d8036608a81e44d183c185e06517e1cf/fd173bc0aba64070b54b049cedcc6bce.jpg, createdBy=41cf5507885, createdName=豪杰克, createdTime=Sun Dec 05 11:23:09 CST 2021, time=2021-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076506, encodeId=e74b10e65065c, content=好用, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d9a5236987, createdName=10188348, createdTime=Fri Dec 03 10:46:36 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076409, encodeId=31bb10e64092e, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Fri Dec 03 06:10:20 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076387, encodeId=dd1410e638736, content=学到了,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95c05717605, createdName=ms3000000092726127, createdTime=Thu Dec 02 23:06:18 CST 2021, time=2021-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076380, encodeId=adde10e6380ab, content=不错,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Thu Dec 02 22:55:49 CST 2021, time=2021-12-02, status=1, ipAttribution=)]
    2021-12-02 仁术2021

    不错,学习了

    0

相关资讯

J Clin Oncol:基于乳腺X线检查的乳腺癌风险预测人工智能模型

乳腺癌在全球女性癌症中的发病率为24.2%,位居女性癌症的首位,其中52.9%发生在发展中国家

Eur J Cancer:Rucaparib治疗BRCA1/2野生型转移性乳腺癌的疗效

小部分不携带胚系BRCA1/2突变的高LOH评分患者也可从PARP抑制剂中获益

平均每周1.2次即可改善心血管和代谢健康!鼓励乳腺癌姐妹动起来!

Scientifc Reports:一项单臂干预研究:在乳腺癌治疗过程中,低频运动训练改善心血管健康和力量

为何这队列中男性乳腺癌风险激增!只因他们都上夜班……

Breast Cancer Res:挪威海上石油工人(NOPW)的男性乳腺癌风险过高:可能与极端夜班工作有关吗?

患者满意度研究结果来了!胸下乳房重建和胸前乳房重建哪种术式会让患者术后幸福感更高?

近年来,胸下乳房植入物在乳房重建中占主导地位,但最近更多地采用胸前乳房植入物重建。迄今为止,比较两种技术的患者报告结果的研究有限。

2021 ACR年会:系统性红斑狼疮是老年早期乳腺癌患者死亡的危险因素

比较患有SLE和BC的女性与单独患有BC的女性或没有癌症的SLE女性的生存率。